Brought to you by 
BI and University of Dundee ink collaboration for PROTACs
29 Apr 2021
Executive Summary
Boehringer Ingelheim GMBH and the University of Dundee entered into a collaboration to develop proteolysis targeting chimeric molecules (PROTACs), which are a novel class of medicines that target disease-causing protein degradation.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI and University of Dundee ink collaboration for PROTACs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice